Inside Lilly Research Laboratories: A Discussion With Jan Lundberg
Executive Summary
Unbowed by a string of recent pipeline setbacks, Lilly Research Labs' new leader speaks out about his company's current trajectory and his belief in ongoing initiatives like Chorus and a mirror fund as Lilly attempts to bridge its patent cliff.
You may also be interested in...
Lilly Antibody Proves Ineffective In Rheumatoid Arthritis, But Lupus Trials Continue
Lilly has stopped one Phase III rheumatoid arthritis trial for its anti-BAFF antibody tabalumab and ceased enrollment in two others after a mid-term analysis revealed a lack of efficacy, but the company is soldiering on with a Phase III program in lupus erythematosus.
Lilly Antibody Proves Ineffective In Rheumatoid Arthritis, But Lupus Trials Continue
Lilly has stopped one Phase III rheumatoid arthritis trial for its anti-BAFF antibody tabalumab and ceased enrollment in two others after a mid-term analysis revealed a lack of efficacy, but the company is soldiering on with a Phase III program in lupus erythematosus.
Unnamed Lilly "Mirror Fund" Acquires First Two Compounds
The acquisitions of two drug candidates - one from Lilly, one from a university - are the first in the pharma's latest scheme to share risk with VCs.